DekaBank Deutsche Girozentrale
TRIB

DekaBank Deutsche Girozentrale’s Trinity Biotech TRIB Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-87
Closed -$89K – 1013
2016
Q4 		$89K Hold
87
– – ﹤0.01% 929
2016
Q3 		$170K Buy
+87
New +$162K ﹤0.01% 852

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

DekaBank Deutsche Girozentrale's TRIB Position: Q1 2017 in Review

DekaBank Deutsche Girozentrale sold out of Trinity Biotech (TRIB) in Q1 2017, closing a stake of 87 shares — an estimated $89K sold.

DekaBank Deutsche Girozentrale first reported a position in TRIB in Q3 2016 and held it in 2 quarters. The position peaked at $170K in Q3 2016. 67 funds tracked by Wall St. Rank hold TRIB as of Q1 2017.

  • DekaBank Deutsche Girozentrale reported no remaining Trinity Biotech position as of Q1 2017 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 87 Trinity Biotech shares in Q1 2017, an estimated $89K.
  • DekaBank Deutsche Girozentrale first reported a position in Trinity Biotech in Q3 2016 and held it in 2 quarters.
  • DekaBank Deutsche Girozentrale's Trinity Biotech position peaked at $170K in Q3 2016.
  • 67 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2017.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2017, filed 2 May 2017.